echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Rheumatology: Rituximab maintenance therapy after remission induction in relapsed or refractory SLE

    Rheumatology: Rituximab maintenance therapy after remission induction in relapsed or refractory SLE

    • Last Update: 2022-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Objective: To investigate the efficacy and safety of rituximab (RTX) maintenance therapy and traditional immunosuppressive (ISA) maintenance therapy in patients with relapsed or refractory systemic lupus erythematosus (SLE)


    Methods: This study was a prospective observational nonrandomized cohort study recruiting SLE patients who received at least one course of RTX induction therapy at four centers


    Patients who were clinically responsive to RTX were divided into two groups based on maintenance therapy in the first 12 months: the RTX group and the ISA group


    Results: Of the 82 patients included in the cohort, 67 (81.


    After a median follow-up of 24 months, a total of 13 patients (19.


    Multivariate analysis identified use of hydroxychloroquine, RTX maintenance therapy, and hematologic involvement as independent predictors of sustained remission


    Conclusions: This multicenter prospective cohort study demonstrates that long-term RTX maintenance therapy has high efficacy and acceptable safety in patients with relapsed or refractory SLE who are clinically responsive to RTX induction therapy


    Source:

    Chen X, Shi X, Xue H, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.